PGT 121
Alternative Names: PGT121; PGT121.414.LS; PGT121LSLatest Information Update: 30 Jul 2024
At a glance
- Originator Theraclone Sciences
- Developer Centre for the AIDS Programme of Research in South Africa; International AIDS Vaccine Initiative; The Ragon Institute of MGH, MIT and Harvard
- Class Antiretrovirals; Antivirals; Monoclonal antibodies
- Mechanism of Action HIV envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 24 Jul 2024 National Institute of Allergy and Infectious Diseases (NIAID) plans a phase I safety and PK trial for HIV-1 infections (In neonates, In volunteers, Monotherapy, combination therapy) in USA, Brazil, Kenya, Puerto Rico and South Africa (SC, Injection) in November 2024 (NCT06517693)
- 18 Jul 2024 National Institute of Allergy and Infectious Diseases (NIAID) plans a phase I/II trial for HIV infections (combination therapy, Treatment experienced, In adults, In adolescent, In childrens) in Botswana (IV, infusion) in September 2024 (NCT06508749)
- 03 Mar 2024 Efficacy data from a phase I/IIa trial in HIV infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 Session (CROI-2024)